News | Artificial Heart | May 27, 2020

First Implantation of Carmat Total Artificial Heart in Denmark

This implant, performed at Rigshospitalet in Copenhagen, marks the resumption of the recruitment in the PIVOTAL study and brings the total number of patients to 13


May 27, 2020 — Carmat, a developer of the of a next generation advanced total artificial heart, announces the first implantation of its bioprosthetic artificial heart in Denmark. The company aims to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure.

The implant procedure was performed by the team of Dr. Peter Skov Olsen, cardiothoracic surgeon at the Heart Center of Rigshospitalet in Copenhagen. It is the first Danish hospital to implant the Carmat total artificial heart and the third international medical center contributing to the PIVOTAL study, together with the Institute for Clinical and Experimental Medicine (IKEM) in Prague, Czech Republic, and the National Research Center for Cardiac Surgery in Nur-Sultan, Kazakhstan.

Finn Gustafsson, M.D., Ph.D., professor of advanced heart failure and transplantation at the Heart Center and principal investigator of the study, comments: "We are excited to gain clinical experience with the Carmat total artificial heart (TAH) and to contribute to the PIVOTAL study. With its hemocompatibility, autoregulation and silent operation, the Cartmat TAH could become a real alternative treatment to heart transplantation for patients suffering from end-stage heart-failure."

"Rigshospitalet has developed a strong expertise in treating advanced heart failure and has participated in front-line clinical studies with innovative medical therapies and devices in this field," said Stéphane Piat, CEO of Carmat. "I am delighted that such an internationally recognized site becomes the third international center to implant our device. With the recent release of certain COVID-19 pandemic-related restrictions, Carmat's teams and proctors were able to prepare and participate in the surgical procedure and early post-operative follow up. To date, 13 patients have received our device in the PIVOTAL study and, subject to the progressive ramp-up in recruitments across our three active study centers, we estimate that 4-5 months are needed to complete enrollment and reach the total of 20 patients."

In accordance with good clinical practice and subject to regulatory obligations or specific circumstances, Carmat will not provide individual updates on patients' implantations or their health condition. However, it is planning to communicate when major milestones in the PIVOTAL study are reached, such as the opening of new centers and the overall progression of patient recruitment.

 

Related Carmat Artificial Heart Content:

Carmat to initiate FDA U.S. Feasibility Study of Total Artificial Heart

Carmat Announces Start of the PIVOTAL Study

VADs Gaining Popularity, But Artificial Hearts Remain the Ideal, Says GlobalData Analyst
 


Related Content

News | Artificial Heart

August 15, 2022 — Researchers in the Biomedical Engineering Department at UConn have developed a new cardiac cell ...

Home August 15, 2022
Home
News | Artificial Heart

July 14, 2022 — University of Toronto Engineering researchers have grown a small-scale model of a human left heart ...

Home July 14, 2022
Home
News | Artificial Heart

April 25, 2022 – There’s no safe way to get a close-up view of the human heart as it goes about its work: you can’t just ...

Home April 25, 2022
Home
News | Artificial Heart

March 28, 2022 — Carmat, the designer and developer of the world’s most advanced total artificial heart, aiming to ...

Home March 28, 2022
Home
News | Artificial Heart

June 18, 2021 – An experimental artificial heart includes an autoregulation control mechanism, or Auto-Mode, that can ...

Home June 23, 2021
Home
News | Artificial Heart

February 10, 2021 - The U.S. Food and Drug Administration (FDA) has granted artificial heart developer Carmat approval ...

Home February 10, 2021
Home
News | Artificial Heart

March 10, 2020 — The U.S. Food and Drug Administration (FDA) has cleared the SynCardia Systems 50cc temporary Total ...

Home March 10, 2020
Home
News | Artificial Heart

December 11, 2017 — CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science ...

Home December 11, 2017
Home
News | Artificial Heart

October 27, 2017 — CorInnova Inc. announced it has received notice of allowance of a seminal patent to protect its ...

Home October 27, 2017
Home
News | Artificial Heart

October 26, 2016 — The U.S. Food and Drug Administration (FDA) provided an update and additional information regarding ...

Home October 26, 2016
Home
Subscribe Now